TP53 and hepatocellular carcinoma: TP53 (Kan et al., 2013), UBE3C (Jiang et al., 2014), SHP-1 (Wen et al., 2018), COL1A1 (Ma et al., 2019), CD5L, and SLC22A10 (Zhang et al., 2019) have been reported to be potential therapeutic targets of HCC by high-throughput sequencing-based bioinformatics analysis.